EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection
Phase 2 Completed
68 enrolled 24 charts
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Phase 1/2 Completed
34 enrolled 18 charts
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Phase 2 Completed
348 enrolled 15 charts
Treatment and Natural History Study of Lymphomatoid Granulomatosis
Phase 2 Completed
94 enrolled 20 charts
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Phase 3 Completed
1,895 enrolled 16 charts
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
Phase 1 Completed
11 enrolled 16 charts
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
Phase 1/2 Completed
107 enrolled 24 charts
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
Phase 2 Completed
194 enrolled 19 charts
Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma
Phase 2 Completed
26 enrolled 18 charts
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Phase 2 Completed
50 enrolled 13 charts
Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
Phase 2 Completed
31 enrolled 12 charts
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
Phase 1 Completed
15 enrolled 18 charts
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 2 Completed
159 enrolled 12 charts
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase 2/3 Completed
63 enrolled 13 charts
Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
Phase 1/2 Completed
49 enrolled 18 charts
AMG 386 and Abiraterone for Advanced Prostate Cancer
Phase 2 Completed
36 enrolled 18 charts
A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer
Phase 2 Completed
63 enrolled 23 charts
Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
Phase 2 Completed
73 enrolled 16 charts
Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy
Phase 1/2 Completed
100 enrolled 10 charts
Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
Phase 2 Completed
60 enrolled 31 charts
Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer
Phase 2 Completed
80 enrolled
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase 2 Completed
148 enrolled 19 charts
UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma
Phase 1 Completed
Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma
Phase 2 Completed
73 enrolled 9 charts
Lenalidomide and Prednisone in Treating Patients With Myelofibrosis
Phase 2 Completed
48 enrolled 7 charts
Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Phase 3 Completed
1,050 enrolled 13 charts
Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma
Phase 2 Completed
30 enrolled
Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia
Phase NA Completed
126 enrolled
Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer
Phase 3 Completed
360 enrolled
STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia
Phase 1/2 Completed
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma
Phase 3 Completed
630 enrolled
Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma
Phase 3 Completed
312 enrolled
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease
Phase 2 Completed
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma
Phase 3 Completed
515 enrolled
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma
Phase 3 Completed
120 enrolled
PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma
Phase 2 Completed
50 enrolled 10 charts
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
Phase 1 Completed
20 enrolled
Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma
Phase 2 Completed
Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
Phase 2 Completed
90 enrolled
Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
Phase 1 Completed